RhumbLine Advisers
CCCC icon

RhumbLine Advisers’s C4 Therapeutics CCCC Stock Holding History

RhumbLine Advisers’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$616K Buy
131,877
+129,161
+4,756% +$442K ﹤0.01% 2623
2026
Q1 		$7.14K Hold
2,716
– – ﹤0.01% 3840
2025
Q4 		$5.19K Hold
2,716
– – ﹤0.01% 3920
2025
Q3 		$6.03K Hold
2,716
– – ﹤0.01% 3902
2025
Q2 		$3.88K Sell
2,716
-86,917
-97% -$126K ﹤0.01% 3941
2025
Q1 		$143K Sell
89,633
-10,382
-10% -$31K ﹤0.01% 3277
2024
Q4 		$360K Buy
100,015
+4,366
+5% +$21.7K ﹤0.01% 2878
2024
Q3 		$545K Buy
95,649
+5,028
+6% +$30.3K ﹤0.01% 2646
2024
Q2 		$419K Buy
90,621
+88,830
+4,960% +$530K ﹤0.01% 2802
2024
Q1 		$14.6K Hold
1,791
– – ﹤0.01% 3808
2023
Q4 		$10.1K Hold
1,791
– – ﹤0.01% 3860
2023
Q3 		$3.33K Sell
1,791
-2,256
-56% -$6.88K ﹤0.01% 4041
2023
Q2 		$11.1K Sell
4,047
-63,041
-94% -$203K ﹤0.01% 3919
2023
Q1 		$211K Buy
67,088
+2,786
+4% +$16.4K ﹤0.01% 2729
2022
Q4 		$379K Buy
64,302
+269
+0.4% +$2.23K ﹤0.01% 2595
2022
Q3 		$562K Buy
64,033
+3,981
+7% +$41.3K ﹤0.01% 2441
2022
Q2 		$453K Buy
60,052
+19,353
+48% +$170K ﹤0.01% 2545
2022
Q1 		$987K Buy
40,699
+2,423
+6% +$58.8K ﹤0.01% 2136
2021
Q4 		$1.23M Buy
38,276
+81
+0.2% +$3.2K ﹤0.01% 2123
2021
Q3 		$1.71M Buy
38,195
+3,630
+11% +$155K ﹤0.01% 1993
2021
Q2 		$1.31M Buy
34,565
+24,284
+236% +$870K ﹤0.01% 2131
2021
Q1 		$380K Buy
10,281
+1,689
+20% +$67.2K ﹤0.01% 2614
2020
Q4 		$285K Buy
+8,592
New +$249K ﹤0.01% 2691

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RhumbLine Advisers's CCCC Position: Q2 2026 in Review

RhumbLine Advisers increased its C4 Therapeutics (CCCC) stake by 4,756% in Q2 2026, buying an estimated $442K and bringing the position to 131,877 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

RhumbLine Advisers first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.71M in Q3 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • RhumbLine Advisers held 131,877 shares of C4 Therapeutics worth $616K as of Q2 2026.
  • RhumbLine Advisers bought 129,161 C4 Therapeutics shares in Q2 2026, an estimated $442K.
  • C4 Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2623 holding.
  • RhumbLine Advisers first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • RhumbLine Advisers's C4 Therapeutics position peaked at $1.71M in Q3 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.